Skip to main content

Krystal Biotech, Inc. (KRYS) Stock Analysis

Range Bound setup

Buy WaitVALUE-TRAP 2/5Moderate Confidence

Healthcare · Biotechnology

Earnings in 3 days (2026-05-04). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Wait for pullback to $252.98. At $265.00 the A.R:R is 0.5:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $252.98 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: VYJUVEK; Thin upside margin: 3.5%.

Krystal Biotech is a commercial-stage biotechnology company using an HSV-1-based gene therapy platform. VYJUVEK is approved in the US, EU, and Japan for dystrophic epidermolysis bullosa (DEB); it launched in the US in 2023 and in Europe and Japan in 2025. The company also has a... Read more

$265.00+7.4% A.UpsideScore 5.1/10#72 of 158 Biotechnology
Entry $252.98(Atr Pullback Sticky)Stop $234.13Target $274.05(analyst − 13%)A.R:R 0.5:1Setup A.R:R 1.8:1
Analyst target$315.00+18.9%9 analysts
$274.05our TP
$265.00price
$315.00mean
$241
$380

Wait for pullback to $252.98. At $265.00 the A.R:R is 0.5:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $252.98 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: VYJUVEK; Thin upside margin: 3.5%. Chart setup: RSI 48 mid-range, Bollinger mid-band. Earnings in 3 days. Wait until post-earnings. Score 5.1/10, moderate confidence.

Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 3d<=7d. Suitability: moderate.

Val3.3Qual7.2Grw5.6Mom2.5Sent6.9Ins3.0Peer5.7Tech6.6Risk5.25.1OVERALL

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Product: VYJUVEK
Thin upside margin: 3.5%
Value-trap signals (2/5): Margin compression (op margin 4.7%), Material insider selling (8 sells, 5.99% of cap)

Key Metrics

P/E (TTM)38.4
P/E (Fwd)25.7
Mkt Cap$7.7B
EV/EBITDA42.0
Profit Mgn52.6%
ROE18.9%
Rev Growth17.5%
Beta0.54
DividendNone
Rating analysts18

Quality Signals

Piotroski F8/9

Options Flow

P/C0.70bullish
IV66%elevated
Max Pain$165-37.7% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHProductVYJUVEK
    10-K Item 1A: 'our near-term prospects, including our ability to develop our product candidates and generate revenue, and our future growth are substantially dependent on the commercial success of VYJUVEK'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Volume
0.0
Obv
1.0
Rsi
5.5
Ma Position
6.0
Volume distribution (falling OBV)Above 200-day MA

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

Ps
0.0
Ev Ebitda
0.0
Pe
3.2
Peg Ratio
4.3
Forward Pe
4.9
Analyst Target
5.0
Forward P/E: 25.7xPEG: 2.22
GatesMomentum 2.5<4.5A.R:R 0.5 < 1.5@spotEARNINGS PROXIMITY 3d<=7dInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARRange BoundSuitability: Moderate
RSI
48 · Neutral
↓ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $252.30Resistance $281.64

Price Targets

$234
$253
$274
A.Upside+3.4%
A.R:R0.5:1
Setup A.R:R (at entry)1.8:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeCautious

Risk Alerts

! Earnings in 3 days - binary event risk
! Momentum score 2.5/10 — below 4.5 minimum
! Reward/Risk 0.5:1 at current price — below 1.5:1 minimum

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-05-04 (3d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is KRYS stock a buy right now?

Wait for pullback to $252.98. At $265.00 the A.R:R is 0.5:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $252.98 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: VYJUVEK; Thin upside margin: 3.5%. Chart setup: RSI 48 mid-range, Bollinger mid-band. Earnings in 3 days. Wait until post-earnings. Target $274.05 (+3.4%), stop $234.13 (−13.2%), Setup A.R:R 1.8:1. Score 5.1/10, moderate confidence.

What is the KRYS stock price target?

Take-profit target: $274.05 (+7.4% upside). Target $274.05 (+3.4%), stop $234.13 (−13.2%), Setup A.R:R 1.8:1. Stop-loss: $234.13.

What are the risks of investing in KRYS?

Concentration risk — Product: VYJUVEK; Thin upside margin: 3.5%; Value-trap signals (2/5): Margin compression (op margin 4.7%), Material insider selling (8 sells, 5.99% of cap).

Is KRYS overvalued or undervalued?

Krystal Biotech, Inc. trades at a P/E of 38.4 (forward 25.7). TrendMatrix value score: 3.3/10. Verdict: Buy (Wait for Entry).

What do analysts say about KRYS?

18 analysts cover KRYS with a consensus score of 4.3/5. Average price target: $315.

What does Krystal Biotech, Inc. do?Krystal Biotech is a commercial-stage biotechnology company using an HSV-1-based gene therapy platform. VYJUVEK is...

Krystal Biotech is a commercial-stage biotechnology company using an HSV-1-based gene therapy platform. VYJUVEK is approved in the US, EU, and Japan for dystrophic epidermolysis bullosa (DEB); it launched in the US in 2023 and in Europe and Japan in 2025. The company also has a pipeline of clinical and pre-clinical candidates.

Related stocks: NVAX (Novavax, Inc.) · INCY (Incyte Corporation) · HRMY (Harmony Biosciences Holdings, I) · AUPH (Aurinia Pharmaceuticals Inc) · CPRX (Catalyst Pharmaceuticals, Inc.)